Navigation Links
Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients
Date:9/6/2008

- Results Demonstrating 95 Percent or Greater Concordance Compared to FISH

and IHC Presented at 2008 ASCO Breast - - Company to Include Reporting for HER2 Gene Expression in All Oncotype DX

Reports by End of 2008 -

REDWOOD CITY, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from two studies demonstrating that quantitative reporting for HER2 gene expression, as measured by the company's Oncotype DX(R) breast cancer assay, has a high degree of concordance with both fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) testing. HER2 is an important marker for therapeutic decision-making for patients with breast cancer, and its measurement significantly impacts the chosen course of treatment. The research was presented at the ASCO Breast Cancer Symposium, September 5-8, 2008, in Washington, D.C.

"Many clinicians who already rely on the Recurrence Score(R) result for treatment planning have specifically requested that we provide the quantitative measure of HER2 gene expression in Oncotype DX reports," said Steven Shak, M.D., chief medical officer of Genomic Health. "Based on this research demonstrating the accuracy and reliability of HER2 measurement using RT-PCR, Oncotype DX can provide additional patient-specific information and insight into each patient's individual tumor biology."

Oncotype DX uses reverse transcription-polymerase chain reaction (RT-PCR) technology to quantify gene expression of 21 genes, one of which is HER2. The two studies found high concordance for testing with Oncotype DX compared to FISH (97 percent) and IHC (95 percent). Earlier this year, Genomic Health increased the clinical
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
2. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
3. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
4. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
5. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
6. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
7. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
8. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
9. Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies
10. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
11. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... -- , Safinamide significantly improves responder ... add-on to levodopa Safinamide is associated ... fluctuating PD patients as add-on to levodopa ... a research and development company focused on novel ... S.p.A., a pharmaceutical company strongly committed to the ...
(Date:6/18/2013)... 18, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... announced today that VPII Escrow Corp., a newly formed ... its offer of approximately $3.2 billion aggregate principal amount ... be due in 2021 and in 2023, with final ... to use the net proceeds from the offering, together ...
(Date:6/18/2013)... June 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... on the development and commercialization of novel bile acid ... pricing of an underwritten public offering of 1,730,000 shares ... of $33.01 per share.  In addition, Intercept has granted ... an additional 259,500 shares of common stock. ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... 1, 2011 Reportlinker.com announces that a new market ... Pen Injectors http://www.reportlinker.com/p0369406/Pen-Injectors.html ... increasing number of drugs in pre-filled disposable cartridges and ... the expense of other drug delivery methods such as ...
... Feb. 1, 2011 Reportlinker.com announces that a ... catalogue: Epoetin alfa - Comprehensive ... Eliminate unnecessary risk with the industry ... Developer is a regularly updated, professional patent search ...
Cached Medicine Technology:Reportlinker Adds Epoetin alfa - Comprehensive patent search 2Reportlinker Adds Epoetin alfa - Comprehensive patent search 3Reportlinker Adds Epoetin alfa - Comprehensive patent search 4
(Date:6/18/2013)... Alabama (PRWEB) June 19, 2013 Consumer ... and two other law firms have launched a new ... injuries caused by dialysis. The website is http://www.DialysisLawsuitAttorneys.com ... was time to begin offering legal services to people ... drugs GranuFlo and NaturaLyte, or who may have suffered ...
(Date:6/18/2013)... 19, 2013 oBand Surgery Centers, a ... holding complimentary weight loss seminars in Los Angeles this ... be accessed at their official website. oBand Surgery Centers ... time. Their highly skilled panel of surgeons and dedicated ... , A senior executive working with oBand Surgery Centers ...
(Date:6/18/2013)... As a sponsor of the 2013 Fourth of July ... Lake Meridian Chiropractic want you to get out and celebrate! ... event and are excited to be involved. “My husband and I ... loved going to the Kent Splash event. It's a tradition that ... to financially support this fun day.” , The 2013 ...
(Date:6/18/2013)... IL (PRWEB) June 18, 2013 Exposed Skin ... helping thousands of acne suffers of all ages finally achieve ... other acne treatment products, this new acne clearing system combines ... acne, and prevent new acne from forming. , ... ExposedSkinCareReview.org believes these products are some of the most effective ...
(Date:6/18/2013)... (PRWEB) June 19, 2013 "What if ... a day could boost your health and well-being? Well, ... founder of Sublime Beauty®. "It is called Skin ... centuries but became a lost art. Now, people are ... about Skin Brushing, and so do certain health conscious ...
Breaking Medicine News(10 mins):Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 2Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 3Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 4Health News:oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June 2Health News:Lake Meridian Chiropractic of Kent, WA to Sponsor the Fireworks Finale at 15th Annual Fourth of July Splash 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2
... RATON, Fla., Sept. 26 Biomedtex Inc.,(Pink Sheets: ... company, announced today that A. Marc Rocca, 42, ... The Company,s mission is to identify, evaluate ... and healthcare solutions, and then,seek to capture and ...
... Consider Proposals and Variations, LOS ANGELES, ... ISCR) a leading e-health Wi-Fi PDA technology ... DME and EMR applications,and the distributor of ... surgical products, announced today that its Board ...
... North America in Deal Valued at up ... to $185 ... 26, NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) and,Nycomed announced ... to Nycomed the rights to develop and commercialize,GATTEX(TM) (teduglutide) outside ...
... ultrasound-guided fine needle to biopsy lymph nodes could spare ... to undergo unnecessary and sometimes unpleasant surgery to verify ... , In a study presented today (Wednesday) at the ... that the less invasive technique produced a false positive ...
... Barcelona, Spain: New research has yielded a clearer picture ... the treatment of colon cancer, bringing closer the day ... spared it, while those that will, get the more ... other solid tumours, doctors plan treatment of colon cancer ...
... to use for older people is the focus of a ... in funding in the latest round of the Australian Research ... design researcher Dr Thea Blackler, is one of 24 projects ... announcement tops off a successful week for QUT research, with ...
Cached Medicine News:Health News:InstaCare Corp. Reviewing M&A Plans 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 3Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 4Health News:Less invasive lymph node biopsy method could spare thousands unnecessary operations 2Health News:Study makes progress in zoning in on biomarkers for better colon cancer treatment 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: